Pure Global AI
NCT06389760Recruiting

Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer: a Prospective, Single-arm, Phase II Trial
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
Nimotuzumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 2
Start date
Oct 18, 2023
End date
Sep 30, 2026
Enrollment
50 participants
Primary outcome

disease-free survival (DFS)

Summary

This is a prospective, multicenter, single-arm, phase II trial. The main purpose of the study
 is to evaluate the efficacy and safety of Nimotuzumab combined with mFOLFIRINOX for
 postoperative adjuvant treatment of pancreatic cancer.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06389760
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06389760 through Pure Global AI's free database. This Phase 2 trial is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.